secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-05-20T11:14:10+00:00
Accession:  0001635088-26-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports Q4 GAAP EPS $0.28 on Moderna settlement; IMVT-1402 D2T RA ACR20 72.7%
--------------------------------------------------------------------------------

- Q4 GAAP income from continuing ops $355.7M ($0.28 diluted EPS) vs loss of $252.4M ($0.29 loss) YoY; includes $770M gain on Moderna settlement.
- Non-GAAP loss from continuing ops $222.7M in Q4 vs $154.4M loss YoY; FY loss $747.7M vs $623.9M.
- IMVT-1402 in D2T RA: Week 16 ACR20 72.7%, ACR50 54.5%, ACR70 35.8% in open-label period; 170 patients enrolled.
- Brepocitinib NDA for DM accepted with Priority Review; launch by end Sep 2026. Breakthrough Therapy for cutaneous sarcoidosis.
- Moderna settlement: $2.25B global; $950M due July 2026; additional $1.3B contingent on appeal resolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/0001635088-26-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/roiv-20260520.htm
  HTML page:      https://secwatch.observer/filing/0001635088-26-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer